Br J Cancer: G3BP1 and YWHAZ Expression Levels: Predictive Indicators of Chemotherapy Resistance and Efficacy for Gastric Cancer.

In China and Western countries, most people with stomach cancer are asymptomatic and have metastasis at the time of initial diagnosis.
Although a variety of treatments are available for the disease, including surgery, chemotherapy, radiotherapy and immunotherapy, the survival of patients with advanced stomach cancer remains poor due to the high recurrence and metastatic nature of the disease.
previous studies have found that many stomach cancer patients are sensitive to drug tolerance and the underlying mechanisms remain unclear.
study shows that stress particles (SGs?? It can protect tumor cells by inhibiting the apoptosis process induced by chemotherapy.
G3BP1, as an effect factor for SG assembly, was detected to express it highly in stomach cancer.
, the study aims to explore the effectiveness of G3BP1 in chemotherapy resistance to stomach cancer.
G3BP1 high expression levels and poor prognostic prognostics in patients receiving complementary chemotherapy compared the survival rates of gastric cancer patients with different G3BP1 expression levels using Kaplan-Meier analysis.
the effects of G3BP1 on chemotherapy resistance and apoptosis of stomach cancer cells.
found that high levels of expression in G3BP1 were associated with poor prognostics in patients with stomach cancer who received complementary chemotherapy.
the expression of the G3BP1 gene can significantly improve the sensitivity of stomach cancer cells to chemotherapy drugs.
mechanism studies have shown that knocking out G3BP1 is accompanied by a significant increase in molecular levels associated with apoptosis and apoptosis.
G3BP1 and YWHAZ in gastric cancer expression gene co-expression network analysis shows that YWHAZ is a key related factor of G3BP1, immunoglostification, immunoseccumulation and immunofluorescence results show that G3BP1 can interact with YWHAZ and chelate the apoptosis regulatory factor Bax in the cytokine, in order to play a role in suppressing apoptosis.
clinical studies showed that patients with high levels of expression, G3BP1 and YWHAZ, showed poor prognostics compared to other patients after chemotherapy.
the G3BP1 interacts with YWHAZ to chelate the apoptosis regulator Bax, the study found that the expression levels of G3BP1 and YWHAZ may be used to predict the effectiveness of complementary chemotherapy in patients with stomach cancer.
.